PolyPeptide signs significant commercial agreement

PolyPeptide / Key word(s): Incoming Orders

19-Dec-2022 / 07:00 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


Media Release – ad hoc announcement pursuant to Art. 53 LR
                       

PolyPeptide signs significant commercial agreement
 

Baar, 19 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the signing of a significant commercial agreement for one of its phase III custom projects.  

As reported with half-year results on 19 August 2022, the custom projects pipeline of PolyPeptide included 218 active projects at the end of June 2022, of which 30 were in phase III of clinical development.

For one of these projects, PolyPeptide has now reached a milestone by signing a multi-year commercial agreement with an annual order value of around EUR 100 million after a ramp-up phase starting in 2024. The agreement is subject to the usual customer confidentiality. It is consistent with the mid-term outlook communicated by PolyPeptide on 19 August 2022 and provides for additional order value potential over time.

This milestone is the result of a successful project collaboration over several years between PolyPeptide and its customer, with whom it maintains a long-standing relationship. For production, PolyPeptide will utilize the new large-scale solid phase synthesis infrastructure that it plans to bring online in Braine-l’Alleud (Belgium) in early 2024. The facility will be deploying advanced technology, resulting in a high degree of automation and productivity.

Raymond De Vré, Chief Executive Officer of PolyPeptide, commented:

“The signing of the agreement reinforces our confidence in the growth opportunities in our market and, more specifically, within our pipeline of phase III custom projects. We are proud to contribute day-by-day to the development and supply of drugs to the benefit of millions of patients.”

 

Contact
PolyPeptide Group AG
Michael Stäheli, Head of Investor Relations & Corporate Communications
michael.staeheli@polypeptide.com, +41 41 723 20 34

About PolyPeptide

PolyPeptide is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide offers products and services from pre-clinical through to commercial stages, including generics. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India with around 1,200 employees as per the middle of 2022. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.

@PolyPeptide – follow us on LinkedIn

 
Disclaimer

This media release has been prepared by PolyPeptide Group AG and includes forward-looking information and statements concerning the outlook for the Group’s business. These statements are based on current expectations, estimates and projections about the factors that may affect its future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as ‘expects’, ‘believes’, ‘estimates’, ‘targets’, ‘plans’, ‘projects’, ‘outlook’ or similar expressions. There are numerous risks, uncertainties and other factors, many of which are beyond PolyPeptide Group AG’s control, that could cause the Group’s actual results to differ materially from the forward-looking information and statements made in this media release and that could affect the Group’s ability to achieve its stated targets. The important factors that could cause such differences include, among others: relationships with employees, customers and other business partners; strategies of competitors; manufacturing capacity and utilization; quality issues; supply chain matters; legal, tax or regulatory disputes; and changes in the political, social and regulatory framework in which the Group operates, or in economic or technological trends or conditions. Although PolyPeptide Group AG believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

Additional features:

File: PolyPeptide_Large order_EN


End of Inside Information


show this